Navigation Links
CuraGen Announces Expansion of CR011-vcMMAE Phase II Trial in Melanoma
Date:6/11/2008

valuating CR011- vcMMAE in patients with advanced melanoma utilizes a Simon 2-Stage design with a primary endpoint of objective response rate. Patients enrolled in the study may have received no more than one prior cytotoxic regimen, but may have received an unlimited number of prior cytokine, immune or vaccine therapies. Enrollment in the study is expected to be completed by the end of 2008.

CR011-vcMMAE targets a protein known as GPNMB, which has been shown to be overexpressed in melanoma, breast cancer and brain tumors. Based on the clinical activity observed in the treatment of melanoma, CuraGen anticipates initiating a Phase II trial evaluating CR011-vcMMAE for the treatment of patients with metastatic breast cancer in the third quarter of 2008. Furthermore, CuraGen is conducting preclinical research to determine the optimal approach for utilizing CR011-vcMMAE as a potential treatment of brain tumors, including glioblastoma multiforme.

CR011-vcMMAE is an antibody-drug conjugate (ADC) comprised of a fully- human monoclonal antibody against glycoprotein NMB (GPNMB) attached to a potent, synthetic drug monomethyl auristatin E (MMAE), using Seattle Genetics' proprietary technology. GPNMB is a novel, selective target that plays a role in the ability of cancer cells to invade and metastasize. CR011-vcMMAE contains an enzyme-cleavable linker designed to be stable in the bloodstream and to release MMAE after internalization into tumor cells that express GPNMB, resulting in cancer cell death.

About Melanoma

The number of people diagnosed with melanoma is rapidly increasing. It is expected that approximately 60,000 new cases of melanoma will be diagnosed and an estimated 8,000 people in the U.S. will die of the disease during 2008. The prognosis for patients with advanced melanoma is poor, and studies have shown that the median survival is less than nine months.

About CuraGen

CuraGen Corporation (Nasdaq:

SOURCE CuraGen Corporation
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. CuraGen Provides Update on Velafermin, Belinostat and CR011-vcMMAE Clinical Development Programs
2. CuraGen and TopoTarget Initiate Phase I/II Clinical Trial of Belinostat (PXD101) Combination Therapy for Acute Myeloid Leukemia
3. CuraGen Announces Top-Line Phase II Results on Velafermin
4. CuraGen Announces Presentation of Phase I Dose-Escalation Results on CR011- vcMMAE for Metastatic Melanoma
5. CuraGen and TopoTarget Announce Presentation of Belinostat Clinical Trial Results at AACR-NCI-EORTC International Conference
6. CuraGen and TopoTarget Announce Presentations on Belinostat at the Upcoming American Society of Hematology 49th Annual Meeting
7. CuraGen Advances CR011-vcMMAE into Phase II
8. CuraGen Announces Data From Ongoing Phase I/II Trial Showing Clinical Activity of CR011-vcMMAE in Metastatic Melanoma
9. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
10. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
11. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/27/2014)... , Aug. 27, 2014  Decision Resources ... specialties (medical oncology, hematology-oncology, rheumatology, gastroenterology, endocrinology and ... trials that a biosimilar has been assessed in ... product they choose to prescribe. ... report entitled Acceptance of Biosimilars Across ...
(Date:8/27/2014)... , Aug. 27, 2014   Los Angeles orthodontics ... AcceleDent® Aura to patients who want to make their ... available at the OrthoSpaceship, all patients have a powerful ... This system can be used by most patients with ... of progress by using the AcceleDent® Aura system for ...
(Date:8/27/2014)... Decision Resources Group finds that the intense ... health system and hospital sector in recent ... Methodist Le Bonheur Healthcare and Baptist Memorial Health Care ... care. In addition, a national contract recently signed between ... enrollment in the Memphis market, ...
Breaking Medicine Technology:Surveyed Physicians Expect to Choose Between Future Biosimilars Based on Robustness and Number of Clinical Trials 2Los Angeles Orthodontist, Dr. Isaac Hakim, is Now Offering AcceleDent Aura 2Memphis-area Health Systems Turn Attention to Clinical Integration 2
... 15, 2011 NewCardio, Inc., (OTC BB: NWCI) a cardiac ... quarter ended June 30, 2011. More details on the financial ... 10-Q, filed today with the Securities and Exchange Commission. ... a top 5 global pharmaceutical company for two Phase I ...
... 15, 2011 For the first time, the ... guidance clarifying how benefit-risk determinations are made during ... (Logo: http://photos.prnewswire.com/prnh/20090824/FDALOGO ) Released today, ... the regulatory pathway for high-risk medical devices. The ...
Cached Medicine Technology:NewCardio Announces Financial Results for Its 2011 Second Quarter 2NewCardio Announces Financial Results for Its 2011 Second Quarter 3NewCardio Announces Financial Results for Its 2011 Second Quarter 4NewCardio Announces Financial Results for Its 2011 Second Quarter 5NewCardio Announces Financial Results for Its 2011 Second Quarter 6NewCardio Announces Financial Results for Its 2011 Second Quarter 7NewCardio Announces Financial Results for Its 2011 Second Quarter 8FDA Proposes Guidelines That Clarify Benefit-Risk Determinations for Medical Devices 2
(Date:8/27/2014)... Home Care Assistance of Scottsdale , ... proud to announce the next installment in its renowned ... Dr. Suzanne Steinbaum, attending cardiologist and Director of Women’s ... City, National Spokesperson for the American Heart Association’s Go ... issues surrounding women and heart disease, what heart disease ...
(Date:8/27/2014)... of clinical trial participation in the largest ongoing observational ... are not representative of the larger patient base, according ... Dr. Jay Udell. The study authors call into question ... population, and suggest the use of broader enrollment criteria ... "We know that clinical trials can be tremendously expensive ...
(Date:8/27/2014)... tested an advanced statistical model to evaluate the ... as published yesterday in Human Genetics . ... in current analyses. Complex diseases like cancer usually ... factors. When many such combinations are studied, identifying ... combinations among affected individuals becomes difficult. In this ...
(Date:8/27/2014)... (PRWEB) August 27, 2014 Cash House ... impact on the overall upkeep of the shelter including new ... importantly helping to change the lives of each youth who ... 35 bed emergency shelter for youth ages 16-25. Not only ... many programs and resources for the youth who come through ...
(Date:8/27/2014)... Lighthouse Payment Services Inc ., a leader ... exhibit its image-based lockbox services at the Independent Bankers ... in beautiful Lake Placid, New York from September 7th ... at the Lake Placid Convention Center and will feature ... addition to a variety of vendors exhibiting the latest ...
Breaking Medicine News(10 mins):Health News:Home Care Assistance of Scottsdale to Host Webinar on Heart Health, Featuring Dr. Suzanne Steinbaum 2Health News:Home Care Assistance of Scottsdale to Host Webinar on Heart Health, Featuring Dr. Suzanne Steinbaum 3Health News:Participants of cardiac clinic trials do not represent real world patients, study finds 2Health News:Dartmouth isolates environmental influences in genome-wide association studies 2Health News:Cash House a Major Supporter of Horizons for Youth 2Health News:Cash House a Major Supporter of Horizons for Youth 3
... (Carlsbad, CA) and its development partner, Logical Therapeutics, Inc. ... active comparator study of LT-NS001 (formerly MX-1094) vs naproxen, ... LT-NS001 is a novel, patented NCE prodrug of the ... developed to significantly reduce the GI safety risks, including ...
... 30-Year Finance Executive Veteran Adds Public Accounting, Executive ... Smith announced today that Dave Watkins has been ... responsible for overseeing all Company financial functions, including ... forecasts and tax planning. H. D. Smith ...
... Time Spent Caring for Parents with Alzheimer,s in Heartfelt New ... memoirs, "36 Days Apart: A memoir of a daughter, her ... Life, Love and Death" ( published by AuthorHouse ... of her mother and father, both of whom were diagnosed ...
... - Discovery Health,s Seventh Annual Programming Event Presents Baby ... 14, through Friday, June 19 - SILVER SPRING, Md., ... the third week of June to deliver the network,s ... pregnancies, to surprise deliveries, to expectant mothers big and ...
... prebiotics market is diversifying and expanding in ... and beverage industry, with several exciting developments ... and the expansion of prebiotic ingredients into ... and meat products.(Logo: http://www.newscom.com/cgi-bin/prnh/20081117/FSLOGO )New prebiotic ...
... of 14 Hydroxycut products, consumers who have suffered injuries from using ... products liability attorney to determine if he/she is eligible for compensation. ... , ... San Diego, CA (PRWEB) May 26, 2009 ...
Cached Medicine News:Health News:Medinox Announces Clinical Results of Naproxen Prodrug 2Health News:H. D. Smith Appoints Dave Watkins Chief Financial Officer 2Health News:New Memoir Details Effects of Alzheimer's on Family 2Health News:Oh Baby! Discovery Health's BABY WEEK Offers the Most Pregnancies, Births and Drama Anywhere on Television 2Health News:Oh Baby! Discovery Health's BABY WEEK Offers the Most Pregnancies, Births and Drama Anywhere on Television 3Health News:Oh Baby! Discovery Health's BABY WEEK Offers the Most Pregnancies, Births and Drama Anywhere on Television 4Health News:European Prebiotics Market Diversifies Strongly Across New Application Sectors in Food and Beverage Industry, Finds Frost & Sullivan 2Health News:European Prebiotics Market Diversifies Strongly Across New Application Sectors in Food and Beverage Industry, Finds Frost & Sullivan 3Health News:European Prebiotics Market Diversifies Strongly Across New Application Sectors in Food and Beverage Industry, Finds Frost & Sullivan 4Health News:European Prebiotics Market Diversifies Strongly Across New Application Sectors in Food and Beverage Industry, Finds Frost & Sullivan 5Health News:European Prebiotics Market Diversifies Strongly Across New Application Sectors in Food and Beverage Industry, Finds Frost & Sullivan 6Health News:European Prebiotics Market Diversifies Strongly Across New Application Sectors in Food and Beverage Industry, Finds Frost & Sullivan 7Health News:LawInfo Provides Access to Qualified Hydroxycut Litigation Attorneys Nationwide 2
... Series from Thermo delivers maximum ... your low-speed clinical applications. With ... system, user-friendly controls, and generous ... Series delivers solid performance for ...
... CL30 Series from Thermo delivers ... for your low-speed clinical applications. ... exchange system, user-friendly controls, and ... CL30 Series delivers solid performance ...
Chembio Diagnostic Systems, Inc.s SURE CHECK HIV 1 / 2, HIV 1/ 2 STAT-PAK and HIV 1/ 2 STAT-PAK Dipstick tests are easy-to-perform, single-use diagnostic tests for the rapid, visual detection of anti...
When you use the optional REAL-Time Continuous Glucose Monitoring Kit with your insulin pump, you will have access to REAL-Time glucose readings, safety alarms, and glucose trend data around the cloc...
Medicine Products: